Conservative Surgery Alone Not Sufficient to Prevent Recurrence

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

BOSTON-Even in a highly selected group of patients with stage I breast cancer, there is a substantial and long-term risk of local recurrence following treatment with conservative surgery without radiotherapy or systemic therapy, May Lim, MD, reported at a general session of the San Antonio Breast Cancer Symposium.

BOSTON—Even in a highly selected group of patients with stage I breast cancer, there is a substantial and long-term risk of local recurrence following treatment with conservative surgery without radiotherapy or systemic therapy, May Lim, MD, reported at a general session of the San Antonio Breast Cancer Symposium.

There is a subset of women who have a low rate of local recurrence following conservative surgery and radiotherapy, but the question has remained as to whether treatment with conservative surgery alone could achieve adequate local control in this group of patients, said Dr. Lim, of the Joint Center for Radiation Therapy, Harvard Medical School.

The 81 patients analyzed in this single-arm, prospective trial all had small T1 tumors (median pathologic size, 0.9 cm), histologically negative axillary lymph nodes, no distant metastases, no extensive intraductal component, no lymphatic vessel invasion, wide excision with negative margins of 1.0 cm or greater, and no adjuvant radiation or systemic therapy. Median age was 66 years; 75% of tumors were detected by mammography alone.

Although these patients were considered to have a good prognosis, at a median follow-up of 92 months, 19 of 81 patients (23%) have had a local recurrence. Time to local recurrence was 7 to 135 months, with a median of 35 months (see Table,).

Other sites of first failure include two patients with contralateral breast cancer, one with ipsilateral axillary node failure, and four with distant metastases. The average annual rate of local recurrence is 2.8 per 100 patient-years of follow-up, and for overall breast cancer recurrence, 3.8 per 100 patient-years of follow-up. Thus far, nine patients have died, four of metastatic breast cancer and five of unrelated causes.

“The implication is that a subgroup of low-risk patients in whom radiation can safely be omitted has not been clearly identified,” Dr. Lim said.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content